CN87103516A - 链霉唑啉与萘醌的迪尔斯-阿勒德尔加成物及其氧化产物的制备方法及其应用 - Google Patents
链霉唑啉与萘醌的迪尔斯-阿勒德尔加成物及其氧化产物的制备方法及其应用 Download PDFInfo
- Publication number
- CN87103516A CN87103516A CN198787103516A CN87103516A CN87103516A CN 87103516 A CN87103516 A CN 87103516A CN 198787103516 A CN198787103516 A CN 198787103516A CN 87103516 A CN87103516 A CN 87103516A CN 87103516 A CN87103516 A CN 87103516A
- Authority
- CN
- China
- Prior art keywords
- formula
- ethanoyl
- compound
- hydrogen
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 7
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract description 30
- 230000003647 oxidation Effects 0.000 title abstract description 7
- 238000007254 oxidation reaction Methods 0.000 title abstract description 7
- 229930192627 Naphthoquinone Natural products 0.000 title abstract description 5
- 150000002791 naphthoquinones Chemical class 0.000 title abstract description 5
- 238000005698 Diels-Alder reaction Methods 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 11
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 27
- -1 methoxyl group Chemical group 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 238000006884 silylation reaction Methods 0.000 claims description 14
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 13
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 13
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 claims description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002841 Lewis acid Substances 0.000 claims description 3
- 150000007517 lewis acids Chemical class 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000003904 antiprotozoal agent Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 208000032839 leukemia Diseases 0.000 abstract description 5
- 239000002423 protozoacide Substances 0.000 abstract description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical group Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- RQNVIKXOOKXAJQ-UHFFFAOYSA-N naphthazarin Chemical class O=C1C=CC(=O)C2=C1C(O)=CC=C2O RQNVIKXOOKXAJQ-UHFFFAOYSA-N 0.000 description 3
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 3
- 229960000641 zorubicin Drugs 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 150000000191 1,4-naphthoquinones Chemical class 0.000 description 1
- NDCQPJCNZBQYAO-UHFFFAOYSA-N 4-[[3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(C=2C3=CC=CC(=C3N=CC=2C(=O)C=2C=CC=CC=2)C(F)(F)F)=C1 NDCQPJCNZBQYAO-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 241000187191 Streptomyces viridochromogenes Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VLZLOWPYUQHHCG-UHFFFAOYSA-N nitromethylbenzene Chemical compound [O-][N+](=O)CC1=CC=CC=C1 VLZLOWPYUQHHCG-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
链霉唑啉经迪尔斯—阿勒德尔反应与萘醌反应,然后将此加成物进行氧化,生成的化合物有细胞毒作用,特别是抗白血病细胞,并且有抗微生物作用和抗原虫作用。
Description
癌症是现时医学上最大的问题之一。大多数癌症病人,由于发生转移而没有一个局部位置可控制肿瘤,不适宜进行外科手术和放射治疗。因此,对新的、具有尽可能少副作用的适宜的化合物日益感到兴趣。根据美国国家肿瘤研究所的资料,现在用于临床上的癌化疗药物,大约有50个天然物质或天然物质的衍生物,还有近百个天然物质处于临床试用的各个阶段。其中蒽类化合物尤其重要,这类有细胞毒作用的化合物已系统地研究了大约25年。
本发明的阐述由链霉唑啉(streptazoline)衍生而得的具有细胞毒性质的化合物。
链霉唑啉(式Ⅳ化合物,R3=H)是策耐尔等(瑞士化学杂志64,1752(1981)从产绿色链霉菌中分离出的,为二级代谢产物,其结构是由科勒-希尔莱因等解折的(瑞士化学杂志65,1432,(1982))。科齐科夫斯基等叙述了链霉唑啉的全合成(美国化学会志107,1763(1984))。
链霉唑啉是非常弱的抗生素,没有细胞毒作用。该化合物或它的相应于式Ⅳ的衍生物与萘醌反应生成的产物,再进一步氧化,生成1,4-二氢蒽醌或蒽醌的衍生物。这类迪尔斯-阿勒德尔加成产物及其氧化产物具有细胞毒作用和抗微生物作用,并有抗原虫作用。
这样,本发明涉及:
1.通式Ⅰ的化合物
式中,R1和R2分别是氢、羟基、甲氧基、O-乙酰基或O-苄基;R3为氢,乙酰基,三甲基硅烷基,二甲基-叔-丁基硅烷基或葡糖基。
2.通式Ⅱ的化合物
式中,在用“O”标出的位置可有两个差向异构体;R1和R2分别是氢,羟基,甲氧基,O-乙酰基或O-苄基;R3为氢,乙酰基,三甲基硅烷基,二甲基-叔-丁基硅烷基或葡糖基。
3.通式Ⅲ的化合物
式中,R1和R2分别是氢,羟基,甲氧基,O-乙酰基或O-苄基;R3是氢,乙酰基,三甲基硅烷基,二甲基-叔-丁基硅烷基或葡糖基。
4.制备通式Ⅰ化合物的方法,该方法包括通式Ⅳ的化合物与通式Ⅴ的化合物反应,
式中R3为氢,乙酰基,三甲基硅烷基,二甲基-叔-丁基硅烷基或葡糖基,R1和R2分别是氢,羟基,甲氧基,O-乙酰基或O-苄基。
5.制备通式Ⅱ和Ⅲ化合物的方法,该方法包括将通式Ⅰ化合物进行氧化。
6.通式Ⅰ、Ⅱ或Ⅲ的化合物作为具有细胞毒活性的药物的应用。
7.通式Ⅰ、Ⅱ或Ⅲ的化合物作为抗微生物或抗原虫药物的应用。
链霉唑啉(Ⅳ,R3=H)可用已知的方法由链霉菌中获取。该化合物及其衍生物,用通式Ⅳ表示,作为迪尔斯-阿勒德尔反应的共轭双烯,加到通式Ⅴ的亲二烯体分子上。反应是在密闭容器中、惰性溶剂和大约60-140℃下进行,反应于4到15小时完成。适宜的溶剂例如有甲苯,硝基甲苯,二甲苯,苯,四氢呋喃或氯仿。当反应物在甲苯中在100到120℃混合时,得到的结果特别好。另外,若R1和R2不是羟基,R3不是氢时,反应物Ⅳ和Ⅴ也可以在二氯甲烷或氯仿中与加入的路易斯酸在-20到+10℃反应,该路易斯酸例如是三氯化铝或四氯化钛。然后将溶剂及催化剂自反应混合物中除去,化合物Ⅰ可用层析法精制。
通式Ⅰ的化合物是制备通式Ⅱ和Ⅲ的化合物的中间体,通式Ⅱ和Ⅲ的化合物的制备是将通式Ⅰ的区域异构或差向异构化合物在C1-C4醇与水的碱性混合物中经氧化而获得的。一般,氧化作用最好是在温度为10到40℃,在水和甲醇(比例为20∶1到1∶20)的溶液中用空气中氧气进行。调节PH为9到14,所用的碱,以氢氧化钠溶液,氢氧化钾溶液,碳酸钠溶液,吡啶或氨水为好。在化合物Ⅰ对水解作用敏感时(例如R1=R2=O-乙酰基,R3=乙酰基),该氧化作用可以在无水甲醇中用吡啶和纯氧进行。
在所述的条件下,经核极化效应测定证实,化合物Ⅱ的形成以绘出的构型占优势,在用“O”标出的位置可以有两种差向异构体。
通式Ⅱ的化合物已证明不是合成通式Ⅲ的化合物的中间体,因为用上述氧化条件不可能由Ⅱ制备Ⅲ。
通式Ⅰ、Ⅱ和Ⅲ的化合物有细胞毒作用,特别是对白血病细胞。此外,这些化合物还有抗微生物作用,尤其是抗真菌作用,特别是对白色念珠菌,还有抗原虫作用,特别是对阴道毛滴虫。
下面的实例对本发明加以详细说明,百分数值是重量百分数。
实例1
400毫克的链霉唑啉(R3=H)(1.93毫摩尔)和367毫克的5,8-二羟基萘醌(R1=R2=OH)(1.93毫摩尔)于100毫升甲苯中,在100到120℃温度下于密闭容器中搅拌10到12小时。然后,真空蒸除溶剂,残留物于硅胶60(默克)上层析,洗脱剂为氯仿/甲醇(95/5)。除掉未反应的链霉唑啉和5,8-二羟基萘醌,得到500毫克迪尔斯-阿勒德尔加成物,为无色的混合物,产物在366nm处有强荧光。若用两倍过量的亲二烯体,反应则臻于完全。
实例2
过程如实例1所述,但用萘醌(R1=R2=H)代替5,8-二羟基萘醌。相应的迪尔斯-阿勒德尔加成物也有类似的产量。
实例3
由实例1得到的迪尔斯-阿勒德尔加成物与20毫升水,60毫升甲醇和20毫升2N氢氧化钠溶液的混合液,室温下空气中搅拌10到15分钟。然后,该溶液用盐酸水溶液调整至PH1,氯仿提取3次,有机层用无水硫酸钠干燥后,真空除去氯仿,得到式Ⅱ的化合物(R1=R2=OH,R3=H)450毫克(按链霉唑啉计,收率59%),式Ⅲ的化合物(R1、R2和R3的含义同上)30毫克(按链霉唑啉计,收率4%)。图1是化合物Ⅱ(R1=R2=OH,R3=H)的1H核磁共振谱。
实例4
过程如实例3所述,但所用的迪尔斯-阿勒德尔加成物是由实例2得到的。得到式Ⅱ的化合物(R1=R2=R3=H)233毫克(按链霉唑啉计,收率31%),和式Ⅲ的化合物(R1=R2=R3=H)149毫克(按链霉唑啉计,收率20%),图2和图3分别是这两个化合物的1H核磁共振谱。
实例5
400毫克链霉唑啉二甲基-叔-丁基硅烷醚(1.24毫摩尔)与196.11毫克(1.24毫摩尔)1,4-萘醌,和165.34毫克三氯化铝,于40毫升二氯甲烷中,0℃下在密闭容器中搅拌30分钟。反应混合物于水及二氯甲烷间分配后,有机相用无水硫酸钠干燥。真空除去二氯甲烷,残留物用硅胶60层析,氯仿/甲醇(95∶5)洗脱,得到迪尔斯-阿勒德尔加成物535毫克(按链霉唑啉二甲基-叔-丁基硅烷醚计,收率90%)。
实例6
由实例5得到的迪尔斯-阿勒德尔加成物在200毫升甲醇和15毫升2N氢氧化钠溶液的混合物中,室温下空气中搅拌15分钟,将此溶液用盐酸水溶液调节至PH3,用氯仿提取3次,无水硫酸钠干燥后,于硅胶60上层析,氯仿/甲醇洗脱(95∶5),得到477毫克的化合物Ⅲ(R1=R2=H,R3=二甲基-叔-丁基硅烷基,按所用的迪尔斯-阿勒德尔加成物计,收率90%)。
实例7
细胞毒作用的实验说明:
化合物的细胞毒作用可在各种试验系统中进行,例如,用小鼠的离体白血病细胞进行软琼脂菌落试验。
在软琼脂上L-1210白血病细胞菌落的形成
这个方法是用来说明受试化合物对数代细胞生长行为的影响(一次细胞周期为10-12小时,7天试验过程可连续观察14代)。在此试验中,有抑制细胞作用的化合物的试验组与对照组比较,可发现菌溶数目的减少。试验的详细方法如下:
受试化合物是由实例3得到的式Ⅱ的化合物,以不同的浓度与每平皿中500个L1210白血病细胞于37℃下温孵4小时。然后用麦克考依5A(MCCOY)媒质将细胞洗涤两次,然后,加入孵0.3%琼脂并倾入到陪替代培养皿中。对照组则仅仅以新媒质温孵。此外,代替1小时温孵的方法,是将不同浓度的受试物质与琼脂上层混合,以便在整个温孵时间内使细胞一直与受试化合物接触。琼脂固化后,平皿置于温箱中于37℃温孵7天(5%二氧化碳,95%相对湿度)。然后,计算直径大于60μ的菌落数。受试组琼脂平皿上的菌落数除以对照组的菌落数的商值表示其结果。受试化合物活性的量度用IC50表示,它是由剂量-效应曲线上得到的。用于本试验的对照化合物是有抑制细胞作用的阿霉素,结果列于表中。
表
物质 干细胞试验浓度 干细胞试验1小时后
IC50(μg/ml) 浓度IC50(μg/ml)
受试物质 0.04 0.26
链霉唑啉 10 10
阿霉素 0.02 0.04
评价
如表所示,由实例3得到的式Ⅱ化合物,其细胞毒作用与阿霉素相当,而起始物质链霉唑啉的细胞毒作用不显著。
Claims (12)
1、式Ⅰ的化合物
式中R1和R2分别是氢,羟基,甲氧基,O-乙酰基或O-苄基,R3为氢,乙酰基,三甲基硅烷基,二甲基-叔-丁基硅烷基或葡糖基。
2、式Ⅱ的化合物
式中在用“O”标示的位置可以有两个差向异构体,R1和R2分别是氢,羟基,甲氧基,O-乙酰基或O-苄基;R3为氢,乙酰基,三甲基硅烷基,二甲基-叔-丁基硅烷基或葡糖基。
5、权利要求4所述的方法,该方法的反应是在甲苯中100到120℃下进行。
6、权利要求4所述的方法,该方法的反应是在-20到+10℃温度下,于二氯甲烷中加入路易斯酸进行。
8、权利要求7所述的方法,该方法的氧化作用是在PH值9到14,于水和C1-C4醇的混合物中,用空气的氧进行。
9、权利要求7所述的方法,该方法的氧化作用是在无水甲醇中用吡啶和纯氧进行。
12、治疗肿瘤的方法,该方法包括给予有效量的有细胞毒作用的通式Ⅰ和/或Ⅱ和/或Ⅲ的化合物,
式中R1和R2分别是氢,羟基,甲氧基,O-乙酰基或O-苄基;R3为氢,乙酰基,三甲基硅烷基,二甲基-叔-丁基硅烷基或葡糖基。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19863616180 DE3616180A1 (de) | 1986-05-14 | 1986-05-14 | Oxidierte diels-alder-addukte mit cytotoxischen eigenschaften, verfahren zu ihrer herstellung aus streptazolin und naphtochinonen und ihre verwendung |
DEP3616180.2 | 1986-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN87103516A true CN87103516A (zh) | 1987-12-30 |
Family
ID=6300783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN198787103516A Pending CN87103516A (zh) | 1986-05-14 | 1987-05-14 | 链霉唑啉与萘醌的迪尔斯-阿勒德尔加成物及其氧化产物的制备方法及其应用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US4849409A (zh) |
EP (1) | EP0245831A3 (zh) |
JP (1) | JPS62273984A (zh) |
CN (1) | CN87103516A (zh) |
AT (1) | AT392277B (zh) |
AU (1) | AU594764B2 (zh) |
CA (1) | CA1286288C (zh) |
DE (1) | DE3616180A1 (zh) |
DK (1) | DK243687A (zh) |
FI (1) | FI84483C (zh) |
IL (1) | IL82502A (zh) |
PT (1) | PT84861B (zh) |
ZA (1) | ZA873426B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT407636B (de) * | 1999-07-09 | 2001-05-25 | Martin Dr Kratzel | Diels-alder-produkte von tetrahydropyridin-dienen mit naphthochinonen und deren oxidationsprodukte, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von arzneimitteln |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2634605C3 (de) * | 1976-07-31 | 1980-09-25 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Anthrachinon |
-
1986
- 1986-05-14 DE DE19863616180 patent/DE3616180A1/de not_active Withdrawn
-
1987
- 1987-05-12 IL IL82502A patent/IL82502A/xx unknown
- 1987-05-12 FI FI872094A patent/FI84483C/fi not_active IP Right Cessation
- 1987-05-12 US US07/048,954 patent/US4849409A/en not_active Expired - Fee Related
- 1987-05-12 EP EP87106832A patent/EP0245831A3/de not_active Withdrawn
- 1987-05-13 ZA ZA873426A patent/ZA873426B/xx unknown
- 1987-05-13 JP JP62114911A patent/JPS62273984A/ja active Pending
- 1987-05-13 PT PT84861A patent/PT84861B/pt not_active IP Right Cessation
- 1987-05-13 DK DK243687A patent/DK243687A/da not_active Application Discontinuation
- 1987-05-13 CA CA000536966A patent/CA1286288C/en not_active Expired - Fee Related
- 1987-05-13 AU AU72787/87A patent/AU594764B2/en not_active Ceased
- 1987-05-14 CN CN198787103516A patent/CN87103516A/zh active Pending
- 1987-10-08 AT AT2578/87A patent/AT392277B/de active
Also Published As
Publication number | Publication date |
---|---|
AT392277B (de) | 1991-02-25 |
EP0245831A2 (de) | 1987-11-19 |
FI872094A0 (fi) | 1987-05-12 |
AU594764B2 (en) | 1990-03-15 |
ATA257887A (de) | 1990-08-15 |
IL82502A (en) | 1991-09-16 |
FI84483B (fi) | 1991-08-30 |
FI84483C (fi) | 1991-12-10 |
DE3616180A1 (de) | 1987-11-19 |
EP0245831A3 (de) | 1989-07-26 |
CA1286288C (en) | 1991-07-16 |
DK243687A (da) | 1987-11-15 |
IL82502A0 (en) | 1987-11-30 |
JPS62273984A (ja) | 1987-11-28 |
US4849409A (en) | 1989-07-18 |
DK243687D0 (da) | 1987-05-13 |
ZA873426B (en) | 1987-11-03 |
FI872094A (fi) | 1987-11-15 |
PT84861A (de) | 1987-06-01 |
PT84861B (pt) | 1990-02-08 |
AU7278787A (en) | 1987-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0149493B1 (ko) | 항종양 항생물질인 ll-e33288의 n-아실 유도체와 그의 제조 방법 및 그의 사용 | |
US6306893B1 (en) | Taxoid derivatives and process for producing the same | |
KR100357541B1 (ko) | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 | |
WO1993014215A1 (en) | Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone | |
EP0388956B1 (en) | Phthalinide derivative, pharmaceutical composition and use | |
GB1589536A (en) | Antitumor anthracycline antibiotics | |
US4837206A (en) | Esperamicin derivatives | |
NO173506B (no) | Fremgangsmaate ved fremtilling av disvovelanaloger av ll-e33288-antitumormidler | |
CN87103516A (zh) | 链霉唑啉与萘醌的迪尔斯-阿勒德尔加成物及其氧化产物的制备方法及其应用 | |
US4863955A (en) | Scytophycins | |
US4303785A (en) | Antitumor anthracycline antibiotics | |
JPS6339000B2 (zh) | ||
Orosz et al. | New semisynthetic vinca alkaloids: chemical, biochemical and cellular studies | |
US5712306A (en) | Physiologically active substances PF1092A, PF1092B and PF1092C, and contraceptives and anticancer drugs containing the same as active ingredients | |
CA1232852A (en) | Cl-1957b antibiotic compound and its production | |
EP0167954B1 (de) | 1-Hydroxy-Cytorhodine, ein mikrobiologisches Verfahren zu ihrer Herstellung und ihre Verwendung als Cytostatika | |
DRAUTZ et al. | Metabolic products of microorganisms. 239 bacimethrin isolated from Streptomyces albus identification, derivatives, synthesis and biological properties | |
EP0186807B1 (de) | Anthracyclin-Derivate, ein mikrobiologisches Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
KANEKO et al. | Two new Veratrum alkaloids, hosukinidine and epirubijervine from illuminated Veratrum plant | |
JP2879394B2 (ja) | ベンズアントラセン誘導体、該誘導体を含有する抗腫瘍剤及びその製造方法 | |
KR100322240B1 (ko) | 페니실리움 속(Penicillium sp.)F70614(KCTC 8918P)와 α-글루코시다제 저해제 | |
JP2821756B2 (ja) | Bu―3862t抗腫瘍性抗生物質 | |
CN101012196A (zh) | 芳香化格尔德霉素类衍生物及其制备方法和用途 | |
EP0408336B1 (en) | Antitumor antibiotic BU-3285T | |
KR100383215B1 (ko) | 신균주 mt90049(kctc 18043p)와 이 균주로부터생산된 신규 화합물과 신규 화합물의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |